226 related articles for article (PubMed ID: 26021891)
1. C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic.
Gil da Costa RM
Vet J; 2015 Jul; 205(1):5-10. PubMed ID: 26021891
[TBL] [Abstract][Full Text] [Related]
2. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours.
Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J
Vet J; 2019 May; 247():71-74. PubMed ID: 30971355
[TBL] [Abstract][Full Text] [Related]
4. Mutation and methylation status of KIT and TP
Vozdova M; Kubickova S; Fictum P; Cernohorska H; Fröhlich J; Rubes J
Vet Comp Oncol; 2020 Sep; 18(3):438-444. PubMed ID: 31574575
[TBL] [Abstract][Full Text] [Related]
5. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
Meyer A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
[TBL] [Abstract][Full Text] [Related]
6. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.
Giantin M; Vascellari M; Morello EM; Capello K; Vercelli A; Granato A; Lopparelli RM; Nassuato C; Carminato A; Martano M; Mutinelli F; Dacasto M
J Vet Diagn Invest; 2012 Jan; 24(1):116-26. PubMed ID: 22362941
[TBL] [Abstract][Full Text] [Related]
7. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.
Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE
Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627
[TBL] [Abstract][Full Text] [Related]
9. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.
Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H
Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
Webster JD; Yuzbasiyan-Gurkan V; Thamm DH; Hamilton E; Kiupel M
BMC Vet Res; 2008 Aug; 4():32. PubMed ID: 18700956
[TBL] [Abstract][Full Text] [Related]
11. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
[TBL] [Abstract][Full Text] [Related]
12. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Einspanier R; Gruber AD; Klopfleisch R
Vet J; 2012 Nov; 194(2):210-4. PubMed ID: 22578690
[TBL] [Abstract][Full Text] [Related]
13. Expression of Phosphorylated KIT in Canine Mast Cell Tumor.
Halsey CHC; Thamm DH; Weishaar KM; Burton JH; Charles JB; Gustafson DL; Avery AC; Ehrhart EJ
Vet Pathol; 2017 May; 54(3):387-394. PubMed ID: 28129097
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
[TBL] [Abstract][Full Text] [Related]
15. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
16. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.
De Vos S; Demeyere K; De Cock H; Devriendt N; Schwarzkopf I; Fortrie R; Roggeman T; Meyer E; De Spiegelaere W; de Rooster H
Res Vet Sci; 2022 Dec; 151():90-95. PubMed ID: 35872552
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Minichromosome Maintenance Protein 7 and c-KIT as Prognostic Markers in Feline Cutaneous Mast Cell Tumours.
Dobromylskyj MJ; Rasotto R; Melville K; Smith KC; Berlato D
J Comp Pathol; 2015 Nov; 153(4):244-50. PubMed ID: 26385324
[TBL] [Abstract][Full Text] [Related]
18. Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors.
Thompson JJ; Morrison JA; Pearl DL; Boston SE; Wood GA; Foster RA; Coomber BL
Vet Pathol; 2016 May; 53(3):545-58. PubMed ID: 26459517
[TBL] [Abstract][Full Text] [Related]
19. Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 May; 148(4):318-22. PubMed ID: 22935087
[TBL] [Abstract][Full Text] [Related]
20. In situ c-KIT mRNA quantification of canine cutaneous mast cell tumours and its relationship to prognostic factors.
Seung BJ; Cho SH; Kim SH; Bae MK; Lim HY; Sur JH
Vet Comp Oncol; 2021 Mar; 19(1):132-139. PubMed ID: 32926564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
